安旭生物(688075.SH):購買1億元隆晟1號信託產品逾期兑付
格隆匯10月8日丨安旭生物(688075.SH)公佈,2022年9月29日,公司使用閒置自有資金10,000.00萬元購買了隆晟1號信託產品。截至本公吿披露日,公司尚未收到本信託計劃的本金及投資收益;公司已就本信託計劃逾期兑付的後續事宜與中融信託進行了多次溝通,截至本公吿披露日,公司未收到中融信託方面的正式文件回覆。
除隆晟1號信託產品,公司未持有其它中融信託發行產品。目前公司經營正常,財務狀況穩健,該事項不影響公司持續運營及日常經營資金需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.